Alzheimer's disease (AD) is the most common cause of dementia, but cognitive decline also occurs in other neurological conditions, such as Parkinson's disease, Lewy body dementia, vascular dementia, and frontotemporal dementia.
Mild cognitive impairment (MCI) is generally defined as cognitive decline that is greater than expected based on an individual's age and level of education, but does not interfere with daily function; it may be a transitional state between the cognitive changes of normal aging and dementia.1
The cholinesterase...
ISSUE
Eylea HD (Regeneron), which contains 8 mg of the vascular endothelial growth factor (VEGF) inhibitor aflibercept, has now been approved by the FDA for intravitreal treatment of macular edema following retinal vein occlusion (RVO). A 2-mg dose of aflibercept (Eylea) was approved previously for this indication. Eylea and Eylea HD are also approved for treatment of neovascular (wet) age-related macular degeneration, diabetic macular edema, and diabetic retinopathy.1
A CLINICAL STUDY — Approval of Eylea HD for the new indication was based on the results of a doublemasked trial (QUASAR) in 892 adults with macular edema following RVO. Patients were randomized to receive aflibercept 8 mg once monthly for 3 or 5 months and then every 8 weeks or aflibercept 2 mg every 4 weeks. Improvements from baseline in best-corrected visual acuity at week 36 with aflibercept 8 mg were …